Published Date: 10 Mar 2023
United States: The US research team recommended using a different agent to enhance the Doppler profile for more accurate measurements.
Read Full NewsThe FDA is requiring new labeling across all GLP-1 receptor agonists to warn of a potential increased risk of a rare, vision-threatening optic nerve condition.
David Leehey, MD, says about half of the 2376 enrolled veterans were taking an SGLT2 inhibitor at baseline.
1.
GLP-1 receptor agonists, cancer risk and questionable significance
2.
Increasing Access to Prostate Cancer Drugs; Reducing Toxic Emissions; FTC Files a 'Charity' Suit.
3.
The risk of cancer is decreased by following international health recommendations.
4.
AI is equally capable of reading breast cancer scans as human radiologists.
5.
Discovery of estrogen receptor 'switches' may aid breast cancer treatment
1.
Epigenome Reprogramming in Cancer: Mechanisms, Clinical Translation, and Therapeutic Opportunities
2.
The Truth About TAR Syndrome: Understanding the Rare Genetic Disorder
3.
Geriatric Oncology and Treatment Sequencing: Evidence-Based Approaches for the Aging Cancer Population
4.
Matrix Metalloproteinases in Stroke: Broad vs. Selective Inhibition Strategies
5.
The Algorithmic Oncologist: A Comparative Clinical Review of AI in Predictive Cancer Planning
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Recognizing the Signs of Anemia in Adults
2.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV
3.
Recognizing Symptoms That May Require Cancer Evaluation
4.
Role of Nimotuzumab in Management of Nasopharyngeal Cancer
5.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation